Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-215007
- Development stage
- Preclinical
- Lead developer
- Aligos Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ALG-215007 is an investigational antisense oligonucleotide (ASO) being developed by Aligos Therapeutics for the treatment of Hepatitis Delta Virus (HDV) infection. Designed as a 5-10-5 MOE-DNA-MOE gapmer, ALG-215007 targets highly conserved regions of the HDV genome or antigenome. By binding to HDV RNA, it potently inhibits viral replication and reduces levels of hepatitis delta antigen (HDAg). The drug is currently in preclinical development, with promising in vitro efficacy data presented at scientific conferences such as AASLD's The Liver Meeting 2026.
- Other names
- ALG 215007ALG215007ALG-215007
02
Targets
HDV RNA (Hepatitis delta virus RNA)
Beyond the preview
Go deeper on ALG-215007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-215007.